AYTU: Aytu BioPharma, Inc. Stock

by  •  • Comments Off on AYTU: Aytu BioPharma, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 9.16
Enterprise Value ($M) 5.61
Book Value ($M) 29.83
Book Value / Share 4.85
Price / Book 0.31
NCAV ($M) -25.27
NCAV / Share -4.11
Price / NCAV -0.36

Profitability (mra)
Return on Invested Capital (ROIC) -0.13
Return on Assets (ROA) -0.05
Return on Equity (ROE) -0.19

Liquidity (mrq)
Quick Ratio 0.80
Current Ratio 0.99

Balance Sheet (mrq) ($M)
Current Assets 60.74
Assets 115.83
Liabilities 86.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 81.00
Operating Income -2.16
Net Income -15.84
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -1.39
Cash from Investing -0.33
Cash from Financing -1.26

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-13 13G/A Stonepine Capital Management, LLC 9.99 10.85
06-18 13D/A Nantahala Capital Management, LLC 18.20 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-09-26 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-02-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-22 9,508 26,097 36.43
2024-11-21 2,008 26,828 7.48
2024-11-20 8,052 28,837 27.92
2024-11-19 1,514 9,471 15.99
2024-11-18 14,904 65,918 22.61

(click for more detail)

Similar Companies
ATYR – aTyr Pharma, Inc. AVTX – Avalo Therapeutics, Inc.
AWH – Aspira Women's Health Inc. BCDA – BioCardia, Inc.
BCLI – Brainstorm Cell Therapeutics Inc.


Financial data and stock pages provided by
Fintel.io